The work of several contractors, including project lead Summertown Interiors, have received praise after Takeda’s new Middle East headquarters were awarded LEED Silver Certification by The U.S. Green Building Council (USGBC).

The offices are located in the One Central Development in the Central Business District of Dubai World Trade Centre Authority (DWTCA) and received the Silver level LEED Certification for ‘Interior Design and Construction: Commercial Interiors’ after achieving over 50 points across several LEED categories.

Summertown Interiors completed the design and build on the Japanese pharmaceutical company’s 2,075sqm office in partnership with Dubai-based interior design firm Roar, and CBRE project management.

Features of the new offices include a boardroom inspired by a Japanese tea house and a reception modeled on a traditional Japanese home’s ‘genkan’ entrance hallway concept. Biophilia and natural materials including wood and raw, exposed concrete were incorporated in the workspace design, alongside the subtle inclusion of the corporate philosophy, “Takeda-ism,” based on four values: integrity, fairness, honesty, and perseverance, explained Summertown Interiors.

“We are delighted to have assisted Takeda to achieve silver-level LEED certification for their new office interior; it was a pleasure to work on such an exciting design and build project,” Marcos Bish, managing director, Summertown Interiors. “I also wish to thank Takeda and the project teams from Roar, CBRE, and Summertown, for support to ensure the project remained on track  despite the outbreak of the COVID-19 pandemic and the new government regulations.”

“This a proud moment for us, and we thank Summertown Interiors, Roar, the CBRE project management teams, and all our partners for their overall contributions towards this project,” said Rodrigo Rodriguez, general manager, Takeda Pharmaceuticals, Middle East Cluster. ” Our latest office investments in Dubai demonstrate our commitment towards the region to ensure better health outcomes for our patients but in a sustainable, environment-friendly way. Our focus is to continue providing cutting-edge innovation to patients, accelerate approval of our treatments, and provide greater access across markets.”